Cargando…
Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex
Susceptibility to multiple sclerosis (MS) is associated with the human histocompatibility leukocyte antigen (HLA)-DR2 haplotype, suggesting that major histocompatibility complex class II–restricted presentation of central nervous system–derived antigens is important in the disease process. Antibodie...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193136/ https://www.ncbi.nlm.nih.gov/pubmed/10770805 |
_version_ | 1782147399641202688 |
---|---|
author | Krogsgaard, Michelle Wucherpfennig, Kai W. Canella, Barbara Hansen, Bjarke E. Svejgaard, Arne Pyrdol, Jason Ditzel, Henrik Raine, Cedric Engberg, Jan Fugger, Lars |
author_facet | Krogsgaard, Michelle Wucherpfennig, Kai W. Canella, Barbara Hansen, Bjarke E. Svejgaard, Arne Pyrdol, Jason Ditzel, Henrik Raine, Cedric Engberg, Jan Fugger, Lars |
author_sort | Krogsgaard, Michelle |
collection | PubMed |
description | Susceptibility to multiple sclerosis (MS) is associated with the human histocompatibility leukocyte antigen (HLA)-DR2 haplotype, suggesting that major histocompatibility complex class II–restricted presentation of central nervous system–derived antigens is important in the disease process. Antibodies specific for defined HLA-DR2–peptide complexes may therefore be valuable tools for studying antigen presentation in MS. We have used phage display technology to select HLA-DR2–peptide-specific antibodies from HLA-DR2–transgenic mice immunized with HLA-DR2 molecules complexed with an immunodominant myelin basic protein (MBP) peptide (residues 85–99). Detailed characterization of one clone (MK16) demonstrated that both DR2 and the MBP peptide were required for recognition. Furthermore, MK16 labeled intra- and extracellular HLA-DR2–MBP peptide complexes when antigen-presenting cells (APCs) were pulsed with recombinant MBP. In addition, MK16 inhibited interleukin 2 secretion by two transfectants that expressed human MBP–specific T cell receptors. Analysis of the structural requirement for MK16 binding demonstrated that the two major HLA-DR2 anchor residues of MBP 85–99 and the COOH-terminal part of the peptide, in particular residues Val-96, Pro-98, and Arg-99, were important for binding. Based on these results, the antibody was used to determine if the HLA-DR2–MBP peptide complex is presented in MS lesions. The antibody stained APCs in MS lesions, in particular microglia/macrophages but also in some cases hypertrophic astrocytes. Staining of APCs was only observed in MS cases with the HLA-DR2 haplotype but not in cases that carried other haplotypes. These results demonstrate that HLA-DR2 molecules in MS lesions present a myelin-derived self-peptide and suggest that microglia/macrophages rather than astrocytes are the predominant APCs in these lesions. |
format | Text |
id | pubmed-2193136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-21931362008-04-16 Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex Krogsgaard, Michelle Wucherpfennig, Kai W. Canella, Barbara Hansen, Bjarke E. Svejgaard, Arne Pyrdol, Jason Ditzel, Henrik Raine, Cedric Engberg, Jan Fugger, Lars J Exp Med Original Article Susceptibility to multiple sclerosis (MS) is associated with the human histocompatibility leukocyte antigen (HLA)-DR2 haplotype, suggesting that major histocompatibility complex class II–restricted presentation of central nervous system–derived antigens is important in the disease process. Antibodies specific for defined HLA-DR2–peptide complexes may therefore be valuable tools for studying antigen presentation in MS. We have used phage display technology to select HLA-DR2–peptide-specific antibodies from HLA-DR2–transgenic mice immunized with HLA-DR2 molecules complexed with an immunodominant myelin basic protein (MBP) peptide (residues 85–99). Detailed characterization of one clone (MK16) demonstrated that both DR2 and the MBP peptide were required for recognition. Furthermore, MK16 labeled intra- and extracellular HLA-DR2–MBP peptide complexes when antigen-presenting cells (APCs) were pulsed with recombinant MBP. In addition, MK16 inhibited interleukin 2 secretion by two transfectants that expressed human MBP–specific T cell receptors. Analysis of the structural requirement for MK16 binding demonstrated that the two major HLA-DR2 anchor residues of MBP 85–99 and the COOH-terminal part of the peptide, in particular residues Val-96, Pro-98, and Arg-99, were important for binding. Based on these results, the antibody was used to determine if the HLA-DR2–MBP peptide complex is presented in MS lesions. The antibody stained APCs in MS lesions, in particular microglia/macrophages but also in some cases hypertrophic astrocytes. Staining of APCs was only observed in MS cases with the HLA-DR2 haplotype but not in cases that carried other haplotypes. These results demonstrate that HLA-DR2 molecules in MS lesions present a myelin-derived self-peptide and suggest that microglia/macrophages rather than astrocytes are the predominant APCs in these lesions. The Rockefeller University Press 2000-04-17 /pmc/articles/PMC2193136/ /pubmed/10770805 Text en © 2000 The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Original Article Krogsgaard, Michelle Wucherpfennig, Kai W. Canella, Barbara Hansen, Bjarke E. Svejgaard, Arne Pyrdol, Jason Ditzel, Henrik Raine, Cedric Engberg, Jan Fugger, Lars Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex |
title | Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex |
title_full | Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex |
title_fullStr | Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex |
title_full_unstemmed | Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex |
title_short | Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex |
title_sort | visualization of myelin basic protein (mbp) t cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (hla)-dr2–mbp 85–99 complex |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193136/ https://www.ncbi.nlm.nih.gov/pubmed/10770805 |
work_keys_str_mv | AT krogsgaardmichelle visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex AT wucherpfennigkaiw visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex AT canellabarbara visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex AT hansenbjarkee visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex AT svejgaardarne visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex AT pyrdoljason visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex AT ditzelhenrik visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex AT rainecedric visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex AT engbergjan visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex AT fuggerlars visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex |